Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated an Outperform rating for Perspective Therapeutics (AMEX:CATX) and maintained a $20 price target.
October 24, 2024 | 2:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst David Nierengarten has reiterated an Outperform rating for Perspective Therapeutics (AMEX:CATX) and maintained a $20 price target.
The reiteration of an Outperform rating and maintenance of a $20 price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in CATX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100